Dr. William Wierda is head of the CLL section there and is leading some innovative research with CARs that could lead to making it less expensive and more accessible for more patients. He explains this leading-edge research in this interview recorded at the 2012 meeting of the American Society of Hematology.
patientpower.info/video/new...
~chris
CLL CANADA cllcanada.ca
Chris, Thanks for forwarding this I think many were waiting for it to hit their mailbox. Good news for Christmas.
The topic is very complicated but this interview i found joined a lot of the dots. I think I understand how the treatment is made CLL specific by designing it to go after ROR1 a protein specific to the tumor cell.
More importantly the long term strategy "that could lead to making it less expensive and more accessible for more patients", Was what I had been waiting to hear. Yes it's on the drawing board and it's a long way away if they can make it happen. But I understand why the experts are so optimistic now.
How long until results from the fist ROR1 CART trials will be available? My thoughts and gratitude are with these brave pioneers and those that are in the early CD19 CART
Nick
Hi This sounds like the thing we have been waiting for. I know its still some way off but its a start. Its hopeful for people like me who hope to stay in remission long enough to enjoy the results of this work. It was also very helpful to have gone to the CLL meeting at GSMK in Sept where some of this protein research was explained. Its good news.
ASH 2012 Interview: Dr Jeff Sharman \"Why New CLL Treatments Supersede FCR\"
An Early Look at When CAR-T Therapy Fails Patients With CLL ASH 2018: Dr. Lindsey Roeker research from ASH 2018 on real world use of venetoclax for CLLASH 2013: INTERVIEW WITH DR. FURMAN RE: IDELALISIBIntroducing Chris Dwyer (Patient Power Video)
